Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RYTM) | Delayed: 89.27 -1.63 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.90 | 52 Week High | $ | |||
| Open | $89.88 | 52 Week Low | $ | |||
| Day High | $90.21 | P/E | N/A | |||
| Day Low | $88.56 | EPS | $ | |||
| Volume | 536,980 | |||||
